



# News Release

## Particle Sciences Receives Patent for Device to Deliver Medication to the Tympanic Membrane

BETHLEHAM, PA, August 1 2018 – As recently announced by the Lubrizol Corporation, Particle Sciences has received a Notice of Allowance on a device for the delivery of medication to the ear-drum.

According to Rob Lee, president, Particle Sciences, “This latest patent is a clear-cut demonstration of our staff going beyond formulation to help our clients deliver a complete solution. It stems from work we did several years back and adds to the increasing pool of proprietary and public domain approaches Particle Sciences can offer its clients. This patent is aimed at providing targeted dosing to the tympanic membrane. We will be looking to partner with our clients on further development and utilization of this invention.”

Particle Sciences, a Lubrizol LifeSciences company, is a leading drug delivery CDMO, an integrated provider of drug development services and manufacturing, and is FDA registered and DEA licensed. Particle Sciences focuses on BCS II/III/IV molecules, biologics and highly potent compounds through a variety of technologies including emulsions, gels, micro and nano-particulates, drug-eluting devices, solid solutions, lyophilization and others.

Through a full range of formulation, analytic and manufacturing services, Particle Sciences provides pharmaceutical companies with a complete and seamless development solution that minimizes the time and risk between discovery and the clinic. The company was founded in 1991 and is headquartered in Bethlehem, Pennsylvania. Visit [www.particlesciences.com](http://www.particlesciences.com), email [info@particlesciences.com](mailto:info@particlesciences.com), or contact us at (610) 861-4701 for information.

Particle Sciences is part of Lubrizol Advanced Materials Inc.

### **About Lubrizol LifeSciences**

Lubrizol LifeSciences is a preferred Contract Development and Manufacturing Organization (CDMO) partner for complex pharmaceuticals and high-end medical devices providing differentiated polymers and excipients, along with state-of-the-art design, development and manufacturing services to the healthcare industry.

### **Media Contact**

Ben Patti

(216) 447-5827

[Benjamin.patti@lubrizol.com](mailto:Benjamin.patti@lubrizol.com)

[www.lubrizol.com/LifeSciences](http://www.lubrizol.com/LifeSciences)

[www.particlesciences.com](http://www.particlesciences.com)

###